Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3612681rdf:typepubmed:Citationlld:pubmed
pubmed-article:3612681lifeskim:mentionsumls-concept:C0007209lld:lifeskim
pubmed-article:3612681lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:3612681lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:3612681lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:3612681pubmed:issue8lld:pubmed
pubmed-article:3612681pubmed:dateCreated1987-9-21lld:pubmed
pubmed-article:3612681pubmed:abstractTextA series of substituted 2-pyridyl-6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-ones 1-24 were synthesized and evaluated for positive inotropic activity. In rats, cats, and dogs most of these tricyclic heterocycles produced a dose-related increase in myocardial contractility with little effect on heart rate and blood pressure. The increase in contractility was not mediated via stimulation of beta-adrenergic receptors. Compound 1 (BM 14.478) was more potent than milrinone (25) and enoximone when administered intravenously to rats, cats, and dogs. After oral administration of 1 mg/kg, compound 1, milrinone, and pimobendan were equipotent. However, only 1 and pimobendan were still active after 6 h. The structural requirements necessary for optimal cardiotonic activity within this novel class of heterocycles were investigated.lld:pubmed
pubmed-article:3612681pubmed:languageenglld:pubmed
pubmed-article:3612681pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3612681pubmed:citationSubsetIMlld:pubmed
pubmed-article:3612681pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3612681pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3612681pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3612681pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3612681pubmed:statusMEDLINElld:pubmed
pubmed-article:3612681pubmed:monthAuglld:pubmed
pubmed-article:3612681pubmed:issn0022-2623lld:pubmed
pubmed-article:3612681pubmed:authorpubmed-author:MertensAAlld:pubmed
pubmed-article:3612681pubmed:authorpubmed-author:Müller-Beckma...lld:pubmed
pubmed-article:3612681pubmed:authorpubmed-author:KampeWWlld:pubmed
pubmed-article:3612681pubmed:authorpubmed-author:von der...lld:pubmed
pubmed-article:3612681pubmed:authorpubmed-author:HölckJ PJPlld:pubmed
pubmed-article:3612681pubmed:issnTypePrintlld:pubmed
pubmed-article:3612681pubmed:volume30lld:pubmed
pubmed-article:3612681pubmed:ownerNLMlld:pubmed
pubmed-article:3612681pubmed:authorsCompleteYlld:pubmed
pubmed-article:3612681pubmed:pagination1279-87lld:pubmed
pubmed-article:3612681pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:meshHeadingpubmed-meshheading:3612681-...lld:pubmed
pubmed-article:3612681pubmed:year1987lld:pubmed
pubmed-article:3612681pubmed:articleTitleNonsteroidal cardiotonics. 1. 2-Pyridyl-6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-ones, a novel class of cardiotonic agents.lld:pubmed
pubmed-article:3612681pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3612681pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:3612681lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3612681lld:pubmed